IDO1 and Hyperglycemia: Overtly diabetic NOD mice, within the first two weeks after hyperglycemia onset, received either a single intraperitoneal injection of IDO-expressing fibroblasts or control injections, including control fibroblasts (mock vector infected) or vehicle solution.